AGAMREE vamorolone

Drug Class

Dissociative corticosteroid

Mechanism

Vamorolone binds to glucocorticoid receptors to exert anti-inflammatory effects while reducing receptor dissociation-associated side effects.

Approved Indication

Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older (FDA) or 4 years and older (NMPA).

What This Means For Patients

Agamree (vamorolone) is a novel dissociative corticosteroid developed to treat Duchenne muscular dystrophy. It provides anti-inflammatory benefits similar to traditional steroids but with a reduced risk of bone loss and growth delay. It is accessible for eligible patients in the Lecheng pilot zone under special-import regulations.

Regulatory Approvals

• FDA — approved (2023) — label
• EMA — approved (2023) — source
• NMPA — approved (2024) — source

Pivotal Clinical Evidence

• VISION-DMD — Guglieri et al., JAMA Neurol 2022 (NCT03439670) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/agamree
• https://doi.org/10.1001/jamaneurol.2022.2480